New Data Presented at the 24th Annual Transcatheter Cardiovascular Therapeutics Scientific Symposium Show Sustained Blood Pressure Reduction and Safety with Symplicity™ Renal Denervation System in Patients with Treatment-Resistant Hypertension
Renal Denervation
New Renal Denervation System Hits The Spot And Delivers Therapy Says Medtronic
Medtronic’s new design multi-electrode radiofrequency renal denervation system builds on experience with the Symplicity™ Renal Denervation System.
Renal Denervation Gets The Healthcare Economic Nod
Medtronic, Inc. has announced findings from a health-economic analysis published online before print in The Journal of the American College of Cardiology that suggest the company’s Symplicity™ renal denervation system is a cost-effective treatment strategy for patients with treatment-resistant hypertension.